Chronic urticaria is a common clinical allergic skin disease. With the development of medicine and the improvement of people’s living standards, the incidence of infectious diseases caused by bacteria such as tuberculosis has decreased significantly, while the body’s exposure to industrial chemicals and dust mites has increased, and these changes in environmental factors have stimulated the body’s Th1/Th2 balance to “drift”. These changes in environmental factors stimulate the body’s Th1/Th2 balance to “drift” and put the body in the so-called “allergic state”, which leads to an increase in the incidence of chronic urticaria, asthma and other allergic diseases. The new antihistamines imipramine and fexofenadine are a new class of antihistamines with both antihistamine and anti-inflammatory effects, which have a strong affinity for histamine H1 receptors and inhibit the release of histamine from mast cells. It is a potent and highly selective histamine H1 receptor antagonist. However, these drugs and glucocorticoids only target the pathological process of chronic urticaria and do not correct the “allergic state” of the body, which is a symptom rather than a cure. BCG polysaccharide nucleic acid, transfer factor, bacterial lysis products and other immunogenic substances of the new immunomodulator, with the regulation and restoration of the body’s Th1/Th2 balance, to correct the body’s “allergic state”, so as to achieve the purpose of the radical treatment of chronic urticaria. Combined with antihistamines, it is an ideal mode of treatment for chronic urticaria, as it can achieve both primary and secondary effects. The results of our study show that this model is effective in the treatment of chronic urticaria and is worthy of clinical application.